GT Biopharma Announces Closing of $23.7 Million Public Offering
Successful completion of NASDAQ uplist
Financing extinguished over $25M in debt and consolidated capital structure to 20,637,000 shares issued and outstanding
Cash runway extended through 2022
BEVERLY HILLS, Calif.–(BUSINESS WIRE)–GT Biopharma, In…